responsiveness, and airway inflammation. During the past decade a growing body of Background -There is increasing evidence to show that leukotrienes are important evidence has shown that leukotrienes play an important part in the pathogenesis of asthma. mediators in asthma. Leukotriene receptor antagonists protect against antigen Moreover, the cysteinyl leukotrienes LTC 4 , LTD 4 , and LTE 4 have been shown potently to and exercise challenges in patients with chronic asthma. A study was undertaken constrict bronchial smooth muscle, stimulate mucous secretions, mediate inflammation, to investigate the activity of the leukotriene receptor antagonist pranlukast (SB and possibly induce bronchial hyperresponsiveness.
normal lung function. None of the study sub-pranlukast or placebo on two occasions separated by at least one week. A histamine chaljects was taking any regular medication and non-steroidal anti-inflammatory drugs were not lenge was performed 3.5 hours after each of these two doses. allowed during the study period. Subjects who developed upper respiratory tract infections
On day 1 of the study subjects presented at the laboratory, having fasted and abstained within six weeks of the start of the study were excluded. All of the men were familiar with from caffeinated beverages since midnight during the preceding night. Baseline measurepulmonary function testing and all gave written informed consent for participation in the study, ments of forced expiratory volume in one second (FEV 1 ) were made three times with a which was approved by the ethics committee of the Royal Brompton National Heart and rolling seal spirometer (P K Morgan, UK).
Specific airways conductance (sGaw) was Lung Hospitals. measured five times using a whole body plethysmograph (Morgan Data Analysis System Version 3.02; P K Morgan) and a mean sGaw  Leukotriene D 4 (Cascade Biochem Ltd, Uni-value was calculated. The subjects then ate a standard breakfast. Thirty minutes later they versity of Reading, UK) was stored at −70°C until immediately before use, at which time it were given the study medication: pranlukast, 450 mg, or matching placebo. Three and a half was dissolved in buffered normal saline solution. The starting LTD 4 concentration was hours later sGaw was measured again and the subjects then underwent LTD 4 inhalation chal-2×10 −6 mol/l. During the challenges this concentration was increased by 3.2 fold lenge.
For the LTD 4 challenges subjects first in-(0.5 log 10 ) increments up to a maximum of 2×10 −4 mol/l. haled buffered normal saline for two minutes.
After an additional two minutes sGaw was Histamine acid phosphate (Northwick Park Hospital, London, UK) was also dissolved in measured five times and the mean value was calculated and used in subsequent analyses as a buffered normal saline solution, and a starting concentration of 0.25 mg/ml (0.8 mol/l) was baseline value. Subjects then inhaled increasing concentrations of LTD 4 . The sGaw was measused. During the challenges the histamine concentrations were increased by doubling, up to ured five times at two and five minutes after each inhalation until either a 35% fall in sGaw a maximum concentration of 32 mg/ml.
from the values after saline was achieved or the aerosol containing the highest LTD 4 concentration was administered. If the decrease in   The challenge aerosols were inhaled using a sGaw was greater than 10% but less than 35% the lung function tests were repeated every 3-5 Wright nebuliser (Clement Clarke, Harlow, Essex, UK) that contained 2 ml of test solution minutes until sGaw values returned to 90% of the post-saline values. The next concentration propelled by compressed air at a flow rate of 7 l/min. Subjects inhaled the aerosol by tidal was not administered until this occurred.
On study day 5 an LTD 4 challenge was breathing by mouth for two minutes, in a manner previously described.
21 22 The nebuliser de-performed according to the same procedure at 3.5 hours and 9.5 hours after the morning dose livered its contents at a rate of 0.16 ml/min. The same flow rate and type of nebuliser were of pranlukast or placebo.
Histamine challenge tests were performed used throughout the study. using the same procedure as was used for the LTD 4 challenges, except that a single set of measurements of sGaw was taken after two   The initial screening of volunteers included a minutes, before proceeding to the next concentration. full physical examination, routine haematology and biochemistry tests, and an electrocardiogram. Haematology and biochemistry tests were performed again on each study day 
In part 1 of the study blood was drawn from and at the end of the study.
the antecubital vein into a heparinised syringe before breakfast on each study day, immediately before and after each LTD 4 challenge at 3.5   The study was divided into two parts and was hours after dosing on days 1 and 5, and before the challenge at 9.5 hours after dosing on day conducted using a randomised, double blind, crossover design in each part which included 5. Plasma was stored at −70°C until plasma concentrations of pranlukast could be assayed at least a one week washout period between the two dosing periods in part 1 of the study by high pressure liquid chromatography. 20 The assay is linear up to 1000 ng/ml, with a lower and between the end of part 1 and start of part 2. In part 1 each subject was given pranlukast, limit of quantification of 10 ng/ml, and is accurate and reproducible to within ±10%. 450 mg, or placebo in two separate repeat dosing periods consisting of four days of twice daily dosing and a single dose on the morning of day 5. LTD 4 challenges were performed at   The PC 35 was calculated from the log con-3.5 hours after dosing on day 1, and at 3.5 and 9.5 hours after dosing on day 5. In part 2 centration-response curve between the two points on either side of a 35% fall in sGaw by each subject received a single 450 mg dose of group.bmj.com on April 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from Values are mean (SD). FEV 1 =forced expiratory volume in one second; sGaw=specific airways conductance.
Results
There was no significant variation in the baseline FEV 1 and sGaw values on the different study days and no change in pulmonary function either after 3.5 hours or 4.5 days of treatment (table 1) . The percentage of baseline sGaw was plotted against the log dose of LTD 4 for each challenge. Subjects treated with pranlukast tolerated significantly higher concentrations of LTD 4 at 3.5 hours after dosing on day 1 and at 3.5 and 9.5 hours after dosing on day 5 than subjects treated with placebo before a 35% decrease in sGaw was observed (fig 1) .
On day 1 the geometric mean PC 35 sGaw for LTD 4 at 3.5 hours after a single 450 mg dose of pranlukast increased 10.6 fold compared with placebo (95% CI 4.4 to 25.5; p<0.001). On day 5, after repeat dosing, the geometric mean PC 35 sGaw for LTD 4 at 3.5 CI 10.8 to 62.2; p<0.001) compared with placebo. Moreover, compared with placebo, a sevenfold increase (95% CI 2.9 to 16.7; p<0.001) in PC 35 sGaw for LTD 4 was still present even at 9.5 hours after dosing on day linear interpolation. 22 For those curves where the maximum dose was reached without achiev-5 (table 2) .
There was no significant difference in the ing a 35% reduction in sGaw, a conservative estimate was made through extrapolation of histamine concentrations for PC 35 sGaw after a single dose of pranlukast compared with the slope of the dose-response curve during active treatment, using the slope of the cor-placebo (shift 1.3 fold; 95% CI 0.6 to 2.7; p= 0.38) (table 2) . responding placebo response. The upper limit of extrapolation was 640 mmol/l for LTD 4 and A positive correlation was observed between log plasma concentrations of pranlukast in 64 mg/ml for histamine.
The data were analysed in each part of the blood samples taken immediately before LTD 4 challenge (3.5 and 9.5 hours after dosing on study by analysis of variance for the two period crossover design, fitting a linear model with day 5) and the log shift in the PC 35 ratio of pranlukast to placebo (r=0.62; 95% CI 0.19 terms for subject, period, treatment, and, for part 1, time and treatment by time interaction. to 0.86; p<0.01; fig 2) .
No changes in haematological or biochemical Logarithmic transformation was applied to PC 35 values prior to statistical analysis.
parameters were noted during the study. The group.bmj.com on April 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from only side effects reported were mild abdominal pranlukast during LTD 4 challenge is positively correlated with plasma concentrations, and the discomfort and loose stools in one subject takpharmacodynamics of the drug appear to be ing pranlukast and mild abdominal discomfort suited to twice daily dosing, with no evidence in one subject taking placebo.
of tachyphylaxis after short term treatment for 4.5 days.
This study was funded by SmithKline Beecham.
Discussion
As in previous studies, the present study dem-
